A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib.
Sponsor: Novartis
Learn more about the REMODEL - Multiple Sclerosis trial or call the Reading Hospital Research Office at 484-628-8585 for more information.
